



months) Bone Marrow Transplantation, 1986 April-October (6

University of Basel, Kantonsspital Basel-Switzerland  
months) Loco-regional Chemotherapy, 1989 September-January (3

University of London, Royal Free Hospital  
Stem Cell Transplantation, 1998

### **III. BOARD CERTIFICATION**

Internal Medicine, 1979  
Medical Oncology, 1983  
Hematology, 1983

### **IV. MEDICAL LICENSURE**

Texas license - licence number: G 1791  
Georgia licence – licence number: 22971  
ESMO Medical oncology certificate – certificate number: 258-495-1

### **V. PREVIOUS PROFESSIONAL POSITIONS AND APPOINTMENTS**

1982-1984 Medicine	Assistant Professor of Internal Medicine, GATA Department of Internal
1984-1989 Medicine,	Associate Professor of Internal Medicine, GATA Department of Internal Division of Medical Oncology
1989-2001 Director )	Professor of Internal Medicine, GATA Department of Internal Medicine (
2001-2006	Chief of Hematology &Oncology Department Professor of Internal Medicine, Kadir Has University School of Medicine Chief of Internal Medicine Department

### **VI. EDUCATION—TEACHING**

1987-1990  
2006

Medical School : GATA School of Medicine: Classes 3 , 4 and 6, 1984-2001  
University of Marmara School of Medicine: Classes 3 and 4,  
Kadir Has University, School of Medicine: Classes 3 and 4, 2001-

Graduate School : İstanbul University Çapa Institute of Oncology  
Courses for Doctorate Students, 1990-1992

Continuing Education : ESMO Courses in Antalya, İstanbul, and Ankara  
Medical Oncology Courses in National Cancer Congresses  
New Trends in Oncology-İstanbul, 2008 and 2009

## **VII. EDUCATION—JOURNALS**

Member of Editorial Board and Reviewer of

- Journal of Hematology and Oncology (Turkey),
- Cancer (Turkey),
- Journal of Oncology (Turkey),
- New Drugs (International)

## **VIII. PROFESSIONAL AND SOCIETY MEMBERSHIPS**

ASCO (American Society of Clinical Oncology)  
ESMO (European Society of Medical Oncology)  
National Society of Medical Oncology  
Turkish Association of Hematology

## **IX. INVITED VISITING PROFESSORSHIPS**

University of London, Charing Cross and Westminster Medical School, 1986  
University of London Royal Free Hospital, 1998

## **X. PRESENTATIONS AT NATIONAL MEETINGS**

More than 200 Oral Presentations in National Meetings\*

## **XI. PRESENTATIONS AT INTERNATIONAL MEETINGS**

More than 100 abstracts and oral presentations in International Congresses \*

## **XII. INTRAMURAL PRESENTATIONS**

Oncology Board, Grand Rounds and Journal Clubs weekly

## **XIII. CLINICAL PRACTICE, INTERESTS, AND ACCOMPLISHMENTS**

Breast cancer, Lung cancer, Gastrointestinal Cancers, Lymphoma, Melanoma, Myeloma, Cancer Vaccines and Targeted therapies

## **XIV. RESEARCH INTERESTS**

Cancer Vaccines and Gene Therapies

### International Multi-National Multicentric and National Multicentric Phase 3 Studies:

1. ISEL Study: Gefitinib in Placebo randomised double blind phase III study in Previously Treated Resistant or Progressive Non-Small Cell Lung Cancer, 2004
2. Efficacy of Docataxel as a First Line Single Agent Compare to Docataxel+ Cisplatin in Stage III/IV Non-Small Cell Lung Cancer, Phase III, Randomised Study, 2000
3. Fluorouracil+ Leucovorine vs Fluorouracil+ alpha Interferon in metastatic Colorectal cancer, Phase III, Randomised Study, 1999
4. Neoadjuvant FOLFIRI vs FOLFOX in the resectability of liver metastases in colo-rectal cancer, Randomized National Multicentric Study
5. Anastrozol Farmacovijilans Study in Early Postmenopausal Breast Cancer Patients, in Turkey. Multicentric National Study (Coordinator), 2008
6. Interferon Maintenance in Multiple Myeloma patients in plato phase, multinational, multicentric study, 1997
7. A Phase III Clinical Trial to Evaluate the safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7. Compared to Dacarbazine(DTIC) or Temozolamide (TMZ) in Subjects with Recurren Metastatic Melanoma Randomized 2010

## **XV. BIBLIOGRAPHY**

More than 200 published articles in National and Internatinal Journals\*

\* List of details can be shared upon the request.